Leap Therapeutics Stock Today
LPTX Stock | USD 2.78 0.30 12.10% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Leap Therapeutics is trading at 2.78 as of the 28th of March 2024; that is 12.10 percent increase since the beginning of the trading day. The stock's open price was 2.48. Leap Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Leap Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 2017 | Category Healthcare | Classification Health Care |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 25.6 M outstanding shares of which 1.13 M shares are now shorted by private and institutional investors with about 4.92 trading days to cover. More on Leap Therapeutics
Moving together with Leap Stock
0.68 | MBRX | Moleculin Biotech Upward Rally | PairCorr |
0.81 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.75 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
Moving against Leap Stock
0.77 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.71 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.57 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.53 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.48 | VANI | Vivani Medical Report 29th of March 2024 | PairCorr |
0.48 | MRK | Merck Company Fiscal Quarter End 31st of March 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
Leap Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Leap Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Leap Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Leap Therapeutics report their recommendations after researching Leap Therapeutics' financial statements, talking to executives and customers, or listening in on Leap Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Leap Therapeutics. The Leap consensus assessment is calculated by taking the average forecast from all of the analysts covering Leap Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Leap Therapeutics' liquidity, profitability, solvency, and operating efficiency, Leap Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Leap Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Leap Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Leap Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Leap Therapeutics' financial leverage. It provides some insight into what part of Leap Therapeutics' total assets is financed by creditors.
|
Leap Therapeutics (LPTX) is traded on NASDAQ Exchange in USA. It is located in 47 Thorndike Street, Cambridge, MA, United States, 02141 and employs 54 people. Leap Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Leap Therapeutics's market, we take the total number of its shares issued and multiply it by Leap Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Leap Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.6 M outstanding shares of which 1.13 M shares are now shorted by private and institutional investors with about 4.92 trading days to cover.
Leap Therapeutics currently holds about 90.88 M in cash with (43.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92.
Check Leap Therapeutics Probability Of Bankruptcy
Ownership AllocationLeap Therapeutics maintains a total of 25.6 Million outstanding shares. 30% of Leap Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Leap Ownership Details
Leap Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Leap Therapeutics jumping above the current price in 90 days from now is about 69.15%. The Leap Therapeutics probability density function shows the probability of Leap Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Leap Therapeutics has a beta of 0.5879. This indicates as returns on the market go up, Leap Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Leap Therapeutics will be expected to be much smaller as well. Additionally, leap Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
Based on a normal probability distribution, the odds of Leap Therapeutics to move above the current price in 90 days from now is about 69.15 (This Leap Therapeutics probability density function shows the probability of Leap Stock to fall within a particular range of prices over 90 days) .
Leap Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Leap Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Leap Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Leap Therapeutics' value.Instituion | Recorded On | Shares | |
Susquehanna International Group, Llp | 2023-12-31 | 127.5 K | |
T. Rowe Price Associates, Inc. | 2023-12-31 | 119.2 K | |
Blackrock Inc | 2023-12-31 | 95.2 K | |
State Street Corporation | 2023-12-31 | 63.2 K | |
Acadian Asset Management Llc | 2023-12-31 | 62.9 K | |
Perceptive Advisors Llc | 2023-12-31 | 45 K | |
Northern Trust Corp | 2023-12-31 | 44.6 K | |
T. Rowe Price Investment Management,inc. | 2023-12-31 | 35.4 K | |
Simplex Trading, Llc | 2023-12-31 | 23.8 K | |
Baker Bros Advisors Lp | 2023-12-31 | 1.2 M | |
Adage Capital Partners Gp Llc | 2023-12-31 | 942.9 K |
Leap Therapeutics Historical Income Statement
Leap Therapeutics Income Statement is one of the three primary financial statements used for reporting Leap's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Leap Therapeutics revenue and expense. Leap Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Leap Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 91.4 M in 2024, whereas Interest Expense is likely to drop 4,750 in 2024. View More FundamentalsLeap Stock Against Markets
Picking the right benchmark for Leap Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Leap Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Leap Therapeutics is critical whether you are bullish or bearish towards Leap Therapeutics at a given time. Please also check how Leap Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Leap Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
All Next | Launch Module |
Leap Therapeutics Corporate Management
Elected by the shareholders, the Leap Therapeutics' board of directors comprises two types of representatives: Leap Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Leap. The board's role is to monitor Leap Therapeutics' management team and ensure that shareholders' interests are well served. Leap Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Leap Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Augustine Lawlor | Chief Officer | Profile | |
Christine Granfield | VP Quality | Profile | |
Mark OMahony | Chief Officer | Profile | |
Jason Baum | Chief Officer | Profile | |
Cynthia Sirard | Chief Officer | Profile | |
Walter Newman | Research Fellow | Profile |
How to buy Leap Stock?
Before investing in Leap Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Leap Therapeutics. To buy Leap Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Leap Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Leap Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Leap Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Leap Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Leap Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.
Already Invested in Leap Therapeutics?
The danger of trading Leap Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Leap Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Leap Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Leap Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Leap Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Leap Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Leap Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Leap Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Leap Stock analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Leap Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Leap Therapeutics. If investors know Leap will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Leap Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.98) | Revenue Per Share 0.003 | Return On Assets (0.75) | Return On Equity (1.37) |
The market value of Leap Therapeutics is measured differently than its book value, which is the value of Leap that is recorded on the company's balance sheet. Investors also form their own opinion of Leap Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Leap Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Leap Therapeutics' market value can be influenced by many factors that don't directly affect Leap Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Leap Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Leap Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Leap Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.